Breaking News

AcelRx Pharmaceuticals Announces Publication of Clinical Data Showing Reduced Hospital Length of Stay and Reduced Opioid Utilization with Use of Sublingual Sufentanil in Total Joint Replacement Surgery

AcelRx Pharmaceuticals Announces Publication of Clinical Data Showing Reduced Hospital Length of Stay and Reduced Opioid Utilization with Use of Sublingual Sufentanil in Total Joint Replacement Surgery

HAYWARD, Calif., Dec. 15, 2021 /PRNewswire/ — AcelRx Prescription drugs, Inc. (NASDAQ: ACRX), a specialty pharmaceutical enterprise focused on the growth and commercialization of innovative therapies for use in medically supervised settings, right now announced the publication of actual-earth information in people going through full hip or full knee substitute demonstrating reduced hospital size of remain and lessened opioid utilization adhering to administration of sublingual sufentanil to handle acute pain when compared to common IV opioids. The write-up was published in the Journal of Orthopaedic Experience and Innovation.

The report entitled “Reduced opioid use and hospital remain in clients going through whole knee or whole hip arthroplasty when addressed with sublingual sufentanil compared with standard analgesic care” was co-authored by Dr. Lawrence Wiesner and Dr. Christian Tvetenstrand from the United Health Services Orthopedic Center in Vestal, New York and Southern Tier Surgical Clinic in Johnson Town, New York. The research prospectively evaluated sufferers who were being administered a one sufentanil sublingual tablet 30 mcg (SST DSUVIA®) in the perioperative time period and in comparison these clients to matched historical regulate patients obtaining conventional IV opioids. The results assessed have been the overall amount of money of opioids administered during the hospital stay (calculated as morphine milligram equivalents), the affected individual size of continue to be, and affected individual disposition at discharge.

A overall of 110 people were evaluated, with 53 people prospectively dealt with with SST and 57 people in the historic comparator team. Client demographics, anesthesia tactics and variety of surgical treatment were equivalent among the teams. Sufferers in both groups averaged in excess of 65 years of age and practically 50% experienced significant systemic condition, described as Bodily Position III by the American Society of Anesthesiologists.

Vital findings bundled the next:

  • The SST group used approximately 30% fewer whole morphine milligram equivalents through their remain (17.8 ± 2.4 vs 25. ± 3.3 for handle sufferers [P < .05]).

  • Clinic duration of keep was close to 30% shorter for the SST group (.87 ± .12 vs 1.23 ± .16 evenings [P < .05]).

  • In the handle team, 9 people (15.8%) had been discharged to a qualified nursing facility in contrast to none in the SST team (P < .01). Their average hospital length of stay was 3.3 ± 0.8 nights prior to discharge to the facility and the average morphine milligram equivalent was 49.1 ± 14.6, almost 3-fold higher than the SST group.

Study limitations include that the control group was a historical cohort, however, both groups received surgery during the COVID pandemic of Summer 2020 and anesthetic techniques, analgesic protocols and discharge criteria were identical between the two groups with the exception of the dosing of SST. Another limitation is that only a single SST dose was evaluated, and it is unclear if additional reductions in opioid utilization might be attained if a second or third dose was utilized over the duration of the patient’s postoperative stay.

“The results from this study showing less overall opioid utilization and more rapid discharge following joint replacement are impressive, especially given the fact that only a single dose of DSUVIA was administered. We used to routinely get calls from the floor nurses the day of surgery when the spinal anesthetic had worn off with patients having rebound pain, but those calls immediately diminished following the adoption of DSUVIA into our current practice,” states lead author Dr. Wiesner. “The joint replacement patients are older and have many comorbidities, therefore it is advantageous to utilize an opioid that not only provides rapid analgesia with initial dosing, but also has a low peak plasma concentration, a high therapeutic index, and a 13-hour terminal half-life allowing lower postoperative opioid requirements and a faster discharge,” continues Dr. Wiesner.

“While Dr. Wiesner and his colleagues practice state-of-the-art multimodal analgesia in their total joint program, by using SST they were able to even further reduce their reliance on IV opioids in the perioperative setting” said Dr. Pamela Palmer, AcelRx Chief Medical Officer and co-founder. “The positive effect this had on patient length of stay and avoiding discharge to a nursing facility is an important clinical outcome for this patient population. Real-world studies continue to show that SST is well tolerated by the older patient population that generally undergoes these total joint procedures,” states Dr. Palmer.

Dr. Wiesner is not a paid consultant for AcelRx. Dr. Tvetenstrand is a paid consultant for AcelRx but was not compensated for this study. AcelRx did not provide funding for the conduct of the study but did fund medical writing support.

About DSUVIA (sufentanil sublingual tablet), 30 mcg
DSUVIA®, known as DZUVEO® in Europe, is indicated for use in adults in certified medically supervised healthcare settings, such as hospitals, surgical centers, and emergency departments, for the management of acute pain severe enough to require an opioid analgesic, and for which alternative treatments are inadequate. DSUVIA was designed to provide rapid analgesia via a non-invasive route and to eliminate dosing errors associated with intravenous (IV) administration. DSUVIA is a single-strength solid dosage form administered sublingually via a single-dose applicator (SDA) by healthcare professionals. Sufentanil is an opioid analgesic previously only marketed for IV and epidural anesthesia and analgesia. The sufentanil pharmacokinetic profile when delivered sublingually avoids the high peak plasma levels and short duration of action observed with IV administration. The European Commission approved DZUVEO for marketing in Europe and it will be commercialized by AcelRx’s European partner, Aguettant.

This release is intended for investors only. For more information, including important safety information and black box warning for DSUVIA, please visit

About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. AcelRx’s proprietary, non-invasive sublingual formulation technology delivers sufentanil with consistent pharmacokinetic profiles. The Company has one approved product in the U.S., DSUVIA® (sufentanil sublingual tablet, 30 mcg), known as DZUVEO® in Europe, indicated for the management of acute pain severe enough to require an opioid analgesic for adult patients in certified medically supervised healthcare settings, and several product candidates. The product candidates include Zalviso® (sufentanil sublingual tablet system, SST system, 15 mcg), an investigational product in the U.S. being developed as an innovatively designed patient-controlled analgesia (PCA) system for reduction of moderate-to-severe acute pain in medically supervised settings, and two pre-filled, ready-to-use syringes of ephedrine and phenylephrine licensed for the U.S. from Aguettant. DZUVEO and Zalviso are both approved products in Europe.

For additional information about AcelRx, please visit

AcelRx logo. (PRNewsFoto/AcelRx Pharmaceuticals, Inc.) (PRNewsfoto/AcelRx Pharmaceuticals, Inc.)



View original content to download multimedia:

SOURCE AcelRx Pharmaceuticals, Inc.

Source link